Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 31, 2026, 1:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 217–240 of 35,326 matching trials from the live ClinicalTrials.gov search.
Filters: Intervention: alone Clear all
Completed Phase 1 Interventional Accepts healthy volunteers

Estimation of the Effect of Multiple Dose Ritlecitinib (PF-06651600) on the Pharmacokinetics of a Single Dose of Caffeine in Healthy Participants

NCT04655040
View directory record Official record
Conditions
Healthy Participants
Interventions
Caffeine, Ritlecitinib
Drug · Other
Lead sponsor
Pfizer
Industry
Eligibility
18 Years to 55 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Mar 18, 2021 · Synced Oct 31, 2026, 1:57 AM EDT
Withdrawn Phase 3 Interventional

A Cross-Over, Multi-Center Trial to Evaluate the Diagnostic Efficacy and Safety of [123I]NAV5001 as an Imaging Agent to Aid in the Diagnosis of Parkinsonian Syndromes

NCT01950468
View directory record Official record
Conditions
Parkinson's Syndrome
Interventions
NAV5001, DaTscan
Drug
Lead sponsor
Navidea Biopharmaceuticals
Industry
Eligibility
40 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2018
U.S. locations
2
States / cities
Phoenix, Arizona • Orlando, Florida
Source: ClinicalTrials.gov public record
Updated Sep 13, 2017 · Synced Oct 31, 2026, 1:57 AM EDT
Recruiting Not applicable Interventional

Prostate Single Port & Laser Enucleation Comparison Trial

NCT06224218
View directory record Official record
Conditions
Prostate Hyperplasia
Interventions
Single Port Robotic Surgery, Laser Surgery
Procedure
Lead sponsor
University of Illinois Chicago
Other
Eligibility
18 Years to 88 Years · Male only
Enrollment
116 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
Chicago, Illinois
Source: ClinicalTrials.gov public record
Updated May 16, 2024 · Synced Oct 31, 2026, 1:57 AM EDT
Completed No phase listed Observational Results available

Building a Multidisciplinary Bridge Across the Quality Chasm in Thoracic Oncology

NCT02123797
View directory record Official record
Conditions
Lung Cancer
Interventions
Not listed
Lead sponsor
Baptist Memorial Health Care Corporation
Other
Eligibility
Not listed
Enrollment
781 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 2, 2020 · Synced Oct 31, 2026, 1:57 AM EDT
Completed No phase listed Observational

Mechanisms of Increased Ambulatory Blood Pressure in Patients With Intradialytic Hypertension

NCT01862497
View directory record Official record
Conditions
Intradialytic Hypertension
Interventions
Carvedilol vs. Prazosin
Drug
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
76 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated May 1, 2018 · Synced Oct 31, 2026, 1:57 AM EDT
Recruiting Phase 1 Interventional

A Study of JNJ-87704916, as Monotherapy and in Combination for Advanced Solid Tumors

NCT06311578
View directory record Official record
Conditions
Neoplasms
Interventions
JNJ-87704916, Cetrelimab, Standard of Care PD(L)-1
Drug
Lead sponsor
Johnson & Johnson Enterprise Innovation Inc.
Industry
Eligibility
18 Years and older
Enrollment
126 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2033
U.S. locations
4
States / cities
New York, New York • Philadelphia, Pennsylvania • Pittsburgh, Pennsylvania + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 25, 2026 · Synced Oct 31, 2026, 1:57 AM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Engineering an Online STI Prevention Program: CSE2

NCT03408743
View directory record Official record
Conditions
Alcohol Consumption, Sexually Transmitted Diseases
Interventions
Knowledge Alone, Self-efficacy alone, Perceived benefits alone, Benefits and self-efficacy, Injunctive norms alone, Injunctive norms and self-efficacy, Injunctive norms and benefits, Injunctive norms, benefits, self-efficacy, Descriptive norms alone, Descriptive norms and self-efficacy, Descriptive norms and perceived benefits, Descriptive norms, benefits, self-efficacy, Descriptive norms and injunctive norms, Descriptive and injunctive norms, self-efficacy, Descriptive and injunctive norms, and benefits, Descriptive & injunctive norms, benefits, efficacy, Expectancies alone, Expectancies and self-efficacy, Expectancies and perceived benefits, Expectancies, benefits, self-efficacy, Expectancies and injunctive norms, Expectancies, injunctive norms, self-efficacy, Expectancies, injunctive norms, and benefits, Expectancies, injunctive norms, benefits, efficacy, Expectancies and descriptive norms, Expectancies, descriptive norms, & self-efficacy, Expectancies, descriptive norms, benefits, Expectancies, descriptive norms, benefits, efficacy, Expectancies, descriptive and injunctive norms, Expectancies, descriptive & injunctive norms, efficacy, Expectancies, descriptive & injunctive norms, benefits, Expectancies, descriptive & injunctive, benefits, efficacy
Behavioral
Lead sponsor
Penn State University
Other
Eligibility
18 Years to 30 Years
Enrollment
2,946 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2017
U.S. locations
4
States / cities
Fresno, California • Fargo, North Dakota • Murfreesboro, Tennessee + 1 more
Source: ClinicalTrials.gov public record
Updated Jul 5, 2019 · Synced Oct 31, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Phase I Dose Escalation Safety Study of RetinoStat in Advanced Age-Related Macular Degeneration (AMD)

NCT01301443
View directory record Official record
Conditions
Age Related Macular Degeneration
Interventions
Subretinally injected RetinoStat
Drug
Lead sponsor
Oxford BioMedica
Industry
Eligibility
50 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
3
States / cities
Iowa City, Iowa • Baltimore, Maryland • Portland, Oregon
Source: ClinicalTrials.gov public record
Updated Apr 5, 2017 · Synced Oct 31, 2026, 1:57 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Dopaminergic Modulation of Frontostriatal Function With a Dopamine Agonist and COMT Inhibitor

NCT02929485
View directory record Official record
Conditions
Addiction
Interventions
Tolcapone, Placebo, Bromocriptine
Drug
Lead sponsor
University of California, Berkeley
Other
Eligibility
18 Years to 50 Years
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
2
States / cities
Berkeley, California • San Francisco, California
Source: ClinicalTrials.gov public record
Updated Nov 16, 2021 · Synced Oct 31, 2026, 1:57 AM EDT
Recruiting Not applicable Interventional

Evaluating Clinical Hiatal Hernia Outcomes Using OviTex®

NCT07070115
View directory record Official record
Conditions
Hiatal Hernia
Interventions
OviTex Reinforced Tissue Matrix
Device
Lead sponsor
Tela Bio Inc
Industry
Eligibility
22 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2032
U.S. locations
5
States / cities
Mobile, Alabama • Denver, Colorado • Lexington, Kentucky + 2 more
Source: ClinicalTrials.gov public record
Updated Aug 18, 2026 · Synced Oct 31, 2026, 1:57 AM EDT
Recruiting Not applicable Interventional

Risk-informed Shared-decision Making Engagement Strategy for Patients With Prediabetes

NCT07553325
View directory record Official record
Conditions
Prediabetes, Prediabetes (Insulin Resistance, Impaired Glucose Tolerance)
Interventions
Risk Informed Shared Decision-Making Strategy (RISE), Low Touch Messaging Strategy (LTM)
Other
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years to 75 Years
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
1
States / cities
Frederick, Maryland
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 31, 2026, 1:57 AM EDT
Completed Not applicable Interventional

Ayurveda Diet & Lifestyle Protocol for Type 2 Diabetes: A Feasibility Study

NCT07400276
View directory record Official record
Conditions
Type 2 Diabetes Mellitus (T2DM)
Interventions
Maharishi Ayurveda Lifestyle Program
Behavioral
Lead sponsor
Maharishi International University
Other
Eligibility
18 Years to 70 Years
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
1
States / cities
Asheville, North Carolina
Source: ClinicalTrials.gov public record
Updated Feb 10, 2026 · Synced Oct 31, 2026, 1:57 AM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Comparing UroLift Experience Against Rezūm

NCT04338776
View directory record Official record
Conditions
Benign Prostatic Hyperplasia
Interventions
UroLift, Rezum
Device
Lead sponsor
NeoTract, Inc.
Industry
Eligibility
50 Years and older · Male only
Enrollment
120 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2021 – 2025
U.S. locations
7
States / cities
Los Angeles, California • Royal Oak, Michigan • Garden City, New York + 4 more
Source: ClinicalTrials.gov public record
Updated Oct 14, 2025 · Synced Oct 31, 2026, 1:57 AM EDT
Enrolling by invitation No phase listed Observational

A Prospective, Single-center, Observational Clinical Outcomes Study for Vertebral Compression Fractures Treated With the OsteoPearl Biological Allograft Implants

NCT07561489
View directory record Official record
Conditions
Kyphoplasty, Vertebroplasty, Vertebral Compression Fracture, Allograft, Back Pain
Interventions
Allograft
Biological
Lead sponsor
Lenoss Medical
Industry
Eligibility
50 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
Williamsville, New York
Source: ClinicalTrials.gov public record
Updated May 1, 2026 · Synced Oct 31, 2026, 1:57 AM EDT
Completed Phase 1Phase 2 Interventional Results available

Sirolimus Injections for Autoimmune Scleritis

NCT01517074
View directory record Official record
Conditions
Scleritis
Interventions
Sirolimus
Drug
Lead sponsor
National Eye Institute (NEI)
NIH
Eligibility
18 Years and older
Enrollment
5 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Jun 19, 2020 · Synced Oct 31, 2026, 1:57 AM EDT
Completed Not applicable Interventional

Physiatrist Ergonomic Intervention on Work Related Musculoskeletal Pain in Surgeons

NCT05946018
View directory record Official record
Conditions
Musculoskeletal Pain, Work Related Stress, Quality of Life, Grip
Interventions
Educational video on ergonomics, Verbal physical therapy coaching sessions
Other
Lead sponsor
University of Texas Southwestern Medical Center
Other
Eligibility
Not listed
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2025
U.S. locations
1
States / cities
Dallas, Texas
Source: ClinicalTrials.gov public record
Updated Jun 4, 2025 · Synced Oct 31, 2026, 1:57 AM EDT
Withdrawn Phase 2 Interventional

Phase-II Study of Lu177DOTATOC in Adults With STTR(+)Pulmonary, Pheochromocytoma, Paraganglioma, Unknown Primary, Thymus NETs (PUTNET), or Any Other Non-.GEP-NET.

NCT04276597
View directory record Official record
Conditions
Pulmonary Neuroendocrine Neoplasm, Pheochromocytoma, Paraganglioma, Thymus Carcinoid, Unknown Primary Tumors, Neuroendocrine Tumors, Neuroendocrine Skin Carcinoma, Neuroendocrine Breast Tumor, Neuroendocrine Carcinoma Metastatic, Neuroendocrine Neoplasm of Ovary
Interventions
177Lu-DOTATOC
Drug
Lead sponsor
Excel Diagnostics and Nuclear Oncology Center
Other
Eligibility
18 Years and older
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 10, 2023 · Synced Oct 31, 2026, 1:57 AM EDT
Completed Phase 1 Interventional

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

NCT01593397
View directory record Official record
Conditions
Obesity
Interventions
Propofol and Fentanyl administration
Drug
Lead sponsor
Stanford University
Other
Eligibility
18 Years to 70 Years
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2017
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 29, 2017 · Synced Oct 31, 2026, 1:57 AM EDT
Terminated Phase 4 Interventional Results available

Effect of Lidocaine and Esmolol to Improve the Quality of Recovery

NCT01114997
View directory record Official record
Conditions
Pain, Constipation, Nausea, Vomiting
Interventions
Lidocaine, Esmolol, Lidocaine + Esmolol (Combo)
Drug
Lead sponsor
Cedars-Sinai Medical Center
Other
Eligibility
18 Years to 80 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2015
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Nov 3, 2016 · Synced Oct 31, 2026, 1:57 AM EDT
Completed Not applicable Interventional Results available

Skin to Skin and Heart Rate Variability

NCT05018910
View directory record Official record
Conditions
Heart Rate Variability, Preterm Infant
Interventions
Skin to Skin
Other
Lead sponsor
University of New Mexico
Other
Eligibility
1 Day to 6 Weeks
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Albuquerque, New Mexico
Source: ClinicalTrials.gov public record
Updated Nov 21, 2024 · Synced Oct 31, 2026, 1:57 AM EDT
Active, not recruiting Phase 1 Interventional

A Study of T-Cell Receptor Engineered Donor T Cells in Subjects Undergoing Allogeneic Peripheral Blood Stem Cell Transplantation (ALLOHA)

NCT05473910
View directory record Official record
Conditions
AML, MDS
Interventions
SOC + TSC-101, Control, SOC + TSC-100
Drug · Other
Lead sponsor
TScan Therapeutics, Inc.
Industry
Eligibility
18 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
21
States / cities
Duarte, California • Aurora, Colorado • Denver, Colorado + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 5, 2026 · Synced Oct 31, 2026, 1:57 AM EDT
Completed Phase 4 Interventional Results available

Phase 4 Comparative Trial of Benzathine Penicillin G for Treatment of Early Syphilis in Subjects With or Without HIV Infection

NCT03637660
View directory record Official record
Conditions
Syphilis
Interventions
Benzathine Penicillin
Drug
Lead sponsor
National Institute of Allergy and Infectious Diseases (NIAID)
NIH
Eligibility
18 Years to 99 Years
Enrollment
249 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2023
U.S. locations
10
States / cities
Birmingham, Alabama • Atlanta, Georgia • Indianapolis, Indiana + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2025 · Synced Oct 31, 2026, 1:57 AM EDT
Terminated Phase 2 Interventional Results available

A Phase II Single Arm Pilot Study of the Chk1/2 Inhibitor (LY2606368) in BRCA1/2 Mutation Associated Breast or Ovarian Cancer, Triple Negative Breast Cancer, High Grade Serous Ovarian Cancer, and Metastatic Castrate-Resistant Prostate Cancer

NCT02203513
View directory record Official record
Conditions
Ovarian Cancer, Breast Cancer, Prostate Cancer
Interventions
LY2606368
Drug
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
111 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
1
States / cities
Bethesda, Maryland
Source: ClinicalTrials.gov public record
Updated Sep 10, 2022 · Synced Oct 31, 2026, 1:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Pilot Study of Lychee Fruit Extract to Promote Cardiovascular Health

NCT01162213
View directory record Official record
Conditions
Cardiovascular Health
Interventions
Lychee Fruit Extract
Dietary Supplement
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 65 Years
Enrollment
44 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2010
U.S. locations
1
States / cities
Davis, California
Source: ClinicalTrials.gov public record
Updated Aug 23, 2010 · Synced Oct 31, 2026, 1:57 AM EDT